JP2010532380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532380A5 JP2010532380A5 JP2010515219A JP2010515219A JP2010532380A5 JP 2010532380 A5 JP2010532380 A5 JP 2010532380A5 JP 2010515219 A JP2010515219 A JP 2010515219A JP 2010515219 A JP2010515219 A JP 2010515219A JP 2010532380 A5 JP2010532380 A5 JP 2010532380A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- formula
- nitrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 115
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 82
- 229910052757 nitrogen Inorganic materials 0.000 claims description 57
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 46
- 239000001301 oxygen Chemical group 0.000 claims description 46
- 229910052760 oxygen Inorganic materials 0.000 claims description 46
- 125000002619 bicyclic group Chemical group 0.000 claims description 45
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 43
- 229910052717 sulfur Chemical group 0.000 claims description 43
- 239000011593 sulfur Chemical group 0.000 claims description 43
- 125000005842 heteroatom Chemical group 0.000 claims description 42
- 125000002950 monocyclic group Chemical group 0.000 claims description 36
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- -1 oxadiadiolyl Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000005306 thianaphthenyl group Chemical group 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- UWCWUCKPEYNDNV-LBPRGKRZSA-N 2,6-dimethyl-n-[[(2s)-pyrrolidin-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C)=C1NC[C@H]1NCCC1 UWCWUCKPEYNDNV-LBPRGKRZSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims description 2
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000005880 oxathiolanyl group Chemical group 0.000 claims description 2
- 125000003544 oxime group Chemical group 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 2
- 125000005503 thioxanyl group Chemical group 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94729107P | 2007-06-29 | 2007-06-29 | |
| US60/947,291 | 2007-06-29 | ||
| PCT/US2008/068762 WO2009006389A2 (en) | 2007-06-29 | 2008-06-30 | Pyrimidine derivatives useful as raf kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013195277A Division JP5962622B2 (ja) | 2007-06-29 | 2013-09-20 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532380A JP2010532380A (ja) | 2010-10-07 |
| JP2010532380A5 true JP2010532380A5 (enExample) | 2012-07-26 |
| JP5649445B2 JP5649445B2 (ja) | 2015-01-07 |
Family
ID=40029124
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515219A Active JP5649445B2 (ja) | 2007-06-29 | 2008-06-30 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
| JP2013195277A Active JP5962622B2 (ja) | 2007-06-29 | 2013-09-20 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
| JP2015043208A Withdrawn JP2015117249A (ja) | 2007-06-29 | 2015-03-05 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013195277A Active JP5962622B2 (ja) | 2007-06-29 | 2013-09-20 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
| JP2015043208A Withdrawn JP2015117249A (ja) | 2007-06-29 | 2015-03-05 | Ｒａｆキナーゼ阻害剤として有用な化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8293752B2 (enExample) |
| EP (2) | EP2167489B1 (enExample) |
| JP (3) | JP5649445B2 (enExample) |
| KR (2) | KR101764076B1 (enExample) |
| CN (3) | CN104370828B (enExample) |
| AR (1) | AR067354A1 (enExample) |
| AU (1) | AU2008273002C1 (enExample) |
| BR (1) | BRPI0813499B8 (enExample) |
| CA (1) | CA2693182C (enExample) |
| CL (1) | CL2008001933A1 (enExample) |
| DK (1) | DK3231798T3 (enExample) |
| ES (2) | ES2776169T3 (enExample) |
| IL (1) | IL202835A (enExample) |
| NZ (1) | NZ582352A (enExample) |
| RU (1) | RU2492166C2 (enExample) |
| TW (1) | TWI444379B (enExample) |
| UA (1) | UA101478C2 (enExample) |
| WO (1) | WO2009006389A2 (enExample) |
| ZA (1) | ZA200909223B (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2167497A2 (en) * | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| MX2010001020A (es) * | 2007-07-26 | 2010-03-01 | Novartis Ag | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. |
| US8399448B2 (en) * | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
| FR2934265B1 (fr) * | 2008-07-23 | 2010-07-30 | Sanofi Aventis | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |
| BRPI0916576A2 (pt) | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
| JP2012514044A (ja) * | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| WO2010111050A1 (en) * | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| AU2010229140A1 (en) * | 2009-03-24 | 2011-11-10 | Msd K.K. | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| EP2440053A4 (en) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
| CA2765030C (en) | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| WO2010144586A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| CA2768924A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| NZ601547A (en) | 2010-01-25 | 2014-04-30 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
| CN102406646B (zh) * | 2010-09-20 | 2015-09-09 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的用途 |
| CN102153515B (zh) * | 2011-02-24 | 2013-02-27 | 中国药科大学 | N,N′-双取代脲类Raf激酶抑制剂及其制备方法和用途 |
| WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| SG2014012926A (en) | 2011-08-30 | 2014-06-27 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013144923A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| EP2922847A1 (en) | 2012-11-20 | 2015-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| JP6392352B2 (ja) | 2013-12-19 | 2018-09-19 | ノバルティス アーゲー | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| MX372995B (es) | 2014-07-17 | 2020-04-13 | Chdi Foundation Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con vih. |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2016106351A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and mtor inhibitors |
| EP3236948A4 (en) * | 2014-12-23 | 2018-10-03 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| US20190117652A1 (en) * | 2014-12-23 | 2019-04-25 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| JP6666673B2 (ja) * | 2015-09-07 | 2020-03-18 | キリンホールディングス株式会社 | 細胞内送達ベヒクル |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| HK1259107A1 (zh) * | 2015-12-11 | 2019-11-22 | 帝人制药株式会社 | 氨基唑衍生物 |
| MA44483A (fr) | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| KR101725292B1 (ko) * | 2016-03-30 | 2017-04-10 | 한국과학기술연구원 | 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체 |
| JP2019196307A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| WO2018200981A1 (en) * | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Raf-degrading conjugate compounds |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CA3065683A1 (en) | 2017-05-30 | 2018-12-06 | Millennium Pharmaceuticals, Inc. | Method for producing optically active compound |
| CA3086765A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| CN114072148A (zh) | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| AU2020368368B2 (en) * | 2019-10-14 | 2026-03-19 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
| AU2020371727B2 (en) | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| EP4065122A4 (en) * | 2019-11-27 | 2023-12-27 | Day One Biopharmaceuticals, Inc. | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR |
| US20230119479A1 (en) * | 2019-12-10 | 2023-04-20 | Shionogi & Co., Ltd. | A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group |
| JP7807381B2 (ja) * | 2020-03-02 | 2026-01-27 | シロナックス リミテッド． | フェロトーシス阻害剤ジアリールアミンパラアセトアミド類 |
| CN115605462B (zh) | 2020-05-12 | 2026-04-14 | 拜耳公司 | 作为杀真菌化合物的三嗪和嘧啶(硫代)酰胺 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| CN117940130A (zh) * | 2021-03-09 | 2024-04-26 | 基因泰克公司 | 用于脑癌治疗的贝伐拉非尼 |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態 |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| JP7894535B2 (ja) | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
| CN117567388B (zh) * | 2023-11-14 | 2024-04-16 | 济南悟通生物科技有限公司 | 一种2-乙酰基-5-噻唑甲酸的合成方法 |
| WO2025264645A1 (en) * | 2024-06-18 | 2025-12-26 | Latigo Biotherapeutics, Inc. | Sodium channel blocking compounds, derivatives thereof, and methods of their use |
| WO2026028053A2 (en) | 2024-07-27 | 2026-02-05 | Assia Chemical Industries Ltd. | Process for the preparation of tovorafenib |
| CN119241530B (zh) * | 2024-09-20 | 2026-04-10 | 武汉九州钰民医药科技有限公司 | 一种Tovorafenib的药物合成工艺 |
| CN119241529B (zh) * | 2024-09-20 | 2026-04-10 | 武汉九州钰民医药科技有限公司 | 一种Tovorafenib的制备方法 |
| CN122145396B (zh) * | 2026-05-11 | 2026-07-24 | 山东百启生物医药有限公司 | 一种5-溴嘧啶-4-甲酸的合成方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US5563158A (en) | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5840917A (en) | 1995-09-26 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Phosphorylamides, their preparation and use |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| JP2000507590A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| HUP0100042A3 (en) | 1996-05-20 | 2003-01-28 | Darwin Discovery Ltd Cambridge | Benzofuran carboxamides medicaments containing the same and their therapeutic use |
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| HUP0000189A3 (en) * | 1996-11-15 | 2002-01-28 | Darwin Discovery Ltd Milton Ro | Bicyclic aryl carboxamides pharmaceutical compositions containing them and their therapeutic use |
| US6017925A (en) | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
| AU6422798A (en) | 1997-03-25 | 1998-10-20 | Takeda Chemical Industries Ltd. | Stabilized urease inhibitor |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| JPH11209366A (ja) | 1998-01-23 | 1999-08-03 | Nissan Chem Ind Ltd | クロマン誘導体及び心不全治療薬 |
| EP0982030A3 (en) | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| WO2000038683A1 (en) | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| CA2367130A1 (en) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| EP1161431A4 (en) | 1999-03-10 | 2002-04-24 | Merck & Co Inc | 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES |
| AU2830800A (en) | 1999-03-25 | 2000-10-16 | Nissan Chemical Industries Ltd. | Chroman derivatives |
| DE19915364A1 (de) | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Verwendung von Arylalkanoylpyridazinen |
| US6127382A (en) | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| CA2392576A1 (en) | 1999-11-24 | 2001-05-31 | Lingyan Wang | .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
| GB0007245D0 (en) | 2000-03-24 | 2000-05-17 | Zeneca Ltd | Chemical compounds |
| EP1296678A2 (en) | 2000-06-21 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| EP1390034A4 (en) | 2001-04-03 | 2005-07-13 | Merck & Co Inc | N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS |
| CA2471566A1 (en) | 2002-01-10 | 2003-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals |
| US20040048866A1 (en) | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
| AU2003243318A1 (en) | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| JP2006502107A (ja) * | 2002-07-02 | 2006-01-19 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｃｒ−３レセプターアンタゴニストｉｘとしての２，５−置換ピリミジン誘導体 |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| EP1547585A4 (en) | 2002-09-25 | 2008-05-14 | Santen Pharmaceutical Co Ltd | THERAPEUTIC AGENT AGAINST RHEUMA WITH A BENZAMIDE DERIVATIVE AS AN ACTIVE SUBSTANCE |
| DE50309381D1 (de) | 2002-11-02 | 2008-04-24 | Sanofi Aventis Deutschland | Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen |
| JP2004161716A (ja) | 2002-11-15 | 2004-06-10 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| DE10328999B4 (de) | 2003-06-27 | 2006-08-31 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte |
| ES2317031T3 (es) | 2003-07-16 | 2009-04-16 | Janssen Pharmaceutica Nv | Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3. |
| NZ545058A (en) | 2003-07-16 | 2008-05-30 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| US7189729B2 (en) | 2003-09-30 | 2007-03-13 | Irm Llc | Methods and compositions as protein kinase inhibitors |
| ES2389203T3 (es) | 2004-01-12 | 2012-10-24 | Ym Biosciences Australia Pty Ltd | Inhibidores de quinasa selectivos |
| WO2005072733A1 (en) | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Dyarylurea compounds as chk-1 inhibitors |
| GB0403635D0 (en) * | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
| US7348346B2 (en) * | 2004-03-08 | 2008-03-25 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| CA2583096A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| EP1820795A4 (en) * | 2004-12-07 | 2010-10-20 | Toyama Chemical Co Ltd | NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT |
| US7767687B2 (en) * | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006076442A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2006101977A2 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
| ES2372976T3 (es) * | 2005-12-13 | 2012-01-30 | Schering Corporation | Derivados de indazol policíclicos que son inhibidores de erk. |
| TW200804349A (en) | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| AU2006332694A1 (en) * | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| CA2639913A1 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceutical Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| EP2086326B1 (en) * | 2006-11-13 | 2014-01-08 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EP2167497A2 (en) | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
-
2008
- 2008-06-27 CL CL2008001933A patent/CL2008001933A1/es unknown
- 2008-06-27 TW TW097124450A patent/TWI444379B/zh active
- 2008-06-27 AR ARP080102801A patent/AR067354A1/es active IP Right Grant
- 2008-06-30 ES ES17168722T patent/ES2776169T3/es active Active
- 2008-06-30 UA UAA200913589A patent/UA101478C2/ru unknown
- 2008-06-30 CN CN201410466320.6A patent/CN104370828B/zh active Active
- 2008-06-30 DK DK17168722.1T patent/DK3231798T3/da active
- 2008-06-30 ES ES08772238.5T patent/ES2635729T3/es active Active
- 2008-06-30 RU RU2009149214/04A patent/RU2492166C2/ru active
- 2008-06-30 CN CN200880022788.9A patent/CN101784545B/zh active Active
- 2008-06-30 US US12/164,762 patent/US8293752B2/en active Active
- 2008-06-30 JP JP2010515219A patent/JP5649445B2/ja active Active
- 2008-06-30 NZ NZ582352A patent/NZ582352A/en not_active IP Right Cessation
- 2008-06-30 EP EP08772238.5A patent/EP2167489B1/en active Active
- 2008-06-30 KR KR1020167004471A patent/KR101764076B1/ko active Active
- 2008-06-30 EP EP17168722.1A patent/EP3231798B1/en active Active
- 2008-06-30 CN CN201611139456.1A patent/CN106957314B/zh active Active
- 2008-06-30 KR KR1020097027037A patent/KR101650140B1/ko active Active
- 2008-06-30 BR BRPI0813499A patent/BRPI0813499B8/pt active IP Right Grant
- 2008-06-30 AU AU2008273002A patent/AU2008273002C1/en active Active
- 2008-06-30 WO PCT/US2008/068762 patent/WO2009006389A2/en not_active Ceased
- 2008-06-30 CA CA2693182A patent/CA2693182C/en active Active
-
2009
- 2009-12-20 IL IL202835A patent/IL202835A/en active IP Right Grant
- 2009-12-23 ZA ZA2009/09223A patent/ZA200909223B/en unknown
-
2012
- 2012-10-22 US US13/657,506 patent/US8802657B2/en active Active
-
2013
- 2013-09-20 JP JP2013195277A patent/JP5962622B2/ja active Active
-
2014
- 2014-07-28 US US14/444,007 patent/US9556177B2/en active Active
-
2015
- 2015-03-05 JP JP2015043208A patent/JP2015117249A/ja not_active Withdrawn
-
2016
- 2016-12-15 US US15/380,515 patent/US9920048B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7631434B2 (ja) | セレブロン（ｃｒｂｎ）に対するリガンド | |
| RU2009149214A (ru) | Соединения, подходящие для применения в качестве ингибиторов киназы raf | |
| JP6147799B2 (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| JP5064024B2 (ja) | イマチニブの製造方法、及び該方法により製造されたイマチニブ | |
| JP2024041923A (ja) | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 | |
| AU2020368392B2 (en) | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | |
| RU2564527C2 (ru) | Производное фталазинонкетона, способ его получения и его фармацевтическое применение | |
| EP4034132B1 (en) | Erk5 degraders as therapeutics in cancer and inflammatory diseases | |
| CN111065390B (zh) | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 | |
| IL263752A (en) | Training modulating compounds | |
| JP7162915B2 (ja) | 置換ピラゾロ［１，５－ａ］ピリミジン系大環状化合物 | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2012514044A5 (enExample) | ||
| IL300308A (en) | Low molecular weight protein complexes and their applications | |
| CN114853754A (zh) | 一种硫代酰胺衍生物及其制备方法和应用 | |
| WO2023143147A1 (zh) | 一种哒嗪并吡啶酮类化合物、其药物组合物及应用 | |
| JP2021520418A (ja) | 高活性ｃｓｆ１ｒ阻害薬化合物 | |
| CN101531653B (zh) | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 | |
| JP2021501215A (ja) | アミノ置換窒素含有縮合環化合物、その調製方法及び使用 | |
| EP3458440A1 (en) | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | |
| JP5319284B2 (ja) | 誘導物及びその各種薬学的に受容可能な塩、５Ｈ−チエノ［３，４−ｃ］ピロール−４，６ジオン誘導物、その調整方法、その使用 | |
| CN118695863A (zh) | 靶向swi/snf相关的基质关联的肌动蛋白依赖性染色质调控因子亚家族a成员4(smarca4) | |
| US20110060010A1 (en) | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof | |
| CN103214467B (zh) | 5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用 | |
| TWI847445B (zh) | 一種噠嗪類化合物、其藥物組合物及應用 |